Publications

Detailed Information

Adiponectin is a potential catabolic mediator in osteoarthritis cartilage

DC Field Value Language
dc.contributor.authorKang, Eun Ha-
dc.contributor.authorLee, Yun Jong-
dc.contributor.authorKim, Tae Kyun-
dc.contributor.authorChang, Chong Bum-
dc.contributor.authorShin, Kichul-
dc.contributor.authorLee, Eun Bong-
dc.contributor.authorSong, Yeong Wook-
dc.contributor.authorLee, Eun Young-
dc.contributor.authorChung, Jin-Haeng-
dc.date.accessioned2012-05-29T06:04:32Z-
dc.date.available2012-05-29T06:04:32Z-
dc.date.issued2010-
dc.identifier.citationARTHRITIS RESEARCH & THERAPY; Vol.12 6; -ko_KR
dc.identifier.issn1478-6354-
dc.identifier.urihttps://hdl.handle.net/10371/76545-
dc.description.abstractIntroduction: Adiponectin has been implicated in the pathogenesis of osteoarthritis (OA). We studied the effects of adiponectin on the OA cartilage homeostasis. Methods: Immunohistochemical analysis was performed to evaluate differential expression of adiponectin receptors (AdipoRs) in nonlesional and lesional areas of OA cartilage. Cartilage and chondrocytes from the knee joints of primary OA patients were cultured in the presence of adiponectin (0 similar to 30 mu g/ml). The levels of total nitric oxide (NO), matrix metalloproteinase (MMP)-1, -3, and -13, and tissue inhibitor of metalloproteinase (TIMP)-1 were measured in the conditioned media. The levels of inducible NO synthase (iNOS) and MMPs were determined with the quantitative real-time reverse transcription-polymerase chain reaction. The concentrations of collagenase-cleaved type II collagen neoepitope (C1-2C) were determined in the supernatant of adiponectin-stimulated OA cartilage explants. The effects of kinase and NOS inhibitors were evaluated in the adiponectin-stimulated chondrocytes. Results: The expression levels of both AdipoR1 and AdipoR2 were significantly higher in lesional than in nonlesional areas of OA cartilage. The increased rate of AdipoR1-positive chondrocytes was twice that of AdipoR2-positive chondrocytes when compared between nonlesional and lesional areas. Adiponectin-stimulated OA chondrocytes showed increased total NO and MMP-1, -3, and -13 levels compared with nonstimulated cells. The TIMP-1 level was not affected. The C1-2C levels were increased by adiponectin in OA cartilage explant culture. AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13. Inducible NOS inhibitors enhanced the expression of the adiponectin-induced MMPs. Conclusions: Adiponectin causes matrix degradation in OA cartilage and increases MMPs and iNOS expression via the AMPK and JNK pathways in human OA chondrocytes. The catabolic effects of adiponectin may be counteracted by NO.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titleAdiponectin is a potential catabolic mediator in osteoarthritis cartilageko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor강은하-
dc.contributor.AlternativeAuthor이윤종-
dc.contributor.AlternativeAuthor김태균-
dc.contributor.AlternativeAuthor장종범-
dc.contributor.AlternativeAuthor정진행-
dc.contributor.AlternativeAuthor신기철-
dc.contributor.AlternativeAuthor이은영-
dc.contributor.AlternativeAuthor이은봉-
dc.contributor.AlternativeAuthor송영욱-
dc.identifier.doi10.1186/ar3218-
dc.citation.journaltitleARTHRITIS RESEARCH & THERAPY-
dc.description.citedreferenceSaxena NK, 2010, GASTROENTEROLOGY, V139, P1762, DOI 10.1053/j.gastro.2010.07.001-
dc.description.citedreferenceChalla TD, 2010, MOL CELL ENDOCRINOL, V323, P282, DOI 10.1016/j.mce.2010.03.025-
dc.description.citedreferenceNishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421-
dc.description.citedreferenceHAO D, 2010, RHEUMATOL INT-
dc.description.citedreferenceLaurberg TB, 2009, J RHEUMATOL, V36, P1885, DOI 10.3899/jrheum.080907-
dc.description.citedreferenceSong HJ, 2009, TRANSL RES, V154, P18, DOI 10.1016/j.trsl.2009.04.003-
dc.description.citedreferenceHuang CY, 2009, EUR J CLIN INVEST, V39, P417, DOI 10.1111/j.1365-2362.2009.02106.x-
dc.description.citedreferenceFilkova M, 2009, ANN RHEUM DIS, V68, P295, DOI 10.1136/ard.2008.095737-
dc.description.citedreferenceYamauchi T, 2008, INT J OBESITY, V32, pS13, DOI 10.1038/ijo.2008.233-
dc.description.citedreferenceLago R, 2008, OSTEOARTHR CARTILAGE, V16, P1101, DOI 10.1016/j.joca.2007.12.008-
dc.description.citedreferenceLee YM, 2008, BIOCHEM BIOPH RES CO, V370, P641, DOI 10.1016/j.bbrc.2008.04.003-
dc.description.citedreferenceHattori Y, 2008, FEBS LETT, V582, P1719, DOI 10.1016/j.febslet.2008.04.037-
dc.description.citedreferenceHaugen F, 2007, ENDOCRINOLOGY, V148, P5478, DOI 10.1210/en.2007-0370-
dc.description.citedreferenceTang CH, 2007, J IMMUNOL, V179, P5483-
dc.description.citedreferenceSchober F, 2007, BIOCHEM BIOPH RES CO, V361, P968, DOI 10.1016/j.bbrc.2007.07.106-
dc.description.citedreferenceAigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534-
dc.description.citedreferenceLegendre F, 2007, CLIN EXP RHEUMATOL, V25, P546-
dc.description.citedreferenceSharma L, 2007, ANN RHEUM DIS, V66, P141, DOI 10.1136/ard.2006.059931-
dc.description.citedreferencePottie P, 2006, ANN RHEUM DIS, V65, P1403, DOI 10.1136/ard.2006.061994-
dc.description.citedreferenceChen TH, 2006, BBA-MOL BASIS DIS, V1762, P711, DOI 10.1016/j.bbadis.2006.06.008-
dc.description.citedreferencePresle N, 2006, OSTEOARTHR CARTILAGE, V14, P690, DOI 10.1016/j.joca.2006.01.009-
dc.description.citedreferenceNeumeier M, 2006, J LEUKOCYTE BIOL, V79, P803, DOI 10.1189/jlb.0905521-
dc.description.citedreferenceLuo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021-
dc.description.citedreferenceMiyazaki T, 2005, BIOCHEM BIOPH RES CO, V333, P79, DOI 10.1016/j.bbrc.2005.05.076-
dc.description.citedreferenceHo LJ, 2005, BIOCHEM PHARMACOL, V70, P200, DOI 10.1016/j.bcp.2005.04.039-
dc.description.citedreferenceKadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005-
dc.description.citedreferenceMeier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482-
dc.description.citedreferenceEnglund M, 2004, ARTHRITIS RHEUM, V50, pS254-
dc.description.citedreferenceSchaffler A, 2003, JAMA-J AM MED ASSOC, V290, P1709-
dc.description.citedreferenceTsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200-
dc.description.citedreferenceWang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200-
dc.description.citedreferenceCooper C, 2000, ARTHRITIS RHEUM, V43, P995-
dc.description.citedreferenceChan ED, 1998, BIOCHEM BIOPH RES CO, V253, P790-
dc.description.citedreferenceHauselmann HJ, 1998, J IMMUNOL, V160, P1444-
dc.description.citedreferenceStefanovicRacic M, 1997, J ORTHOPAED RES, V15, P442-
dc.description.citedreferenceTamura T, 1996, ENDOCRINOLOGY, V137, P3729-
dc.description.citedreferenceStefanovicRacic M, 1996, J IMMUNOL, V156, P1213-
dc.description.citedreferenceMURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15-
dc.description.citedreferenceREGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338-
dc.description.citedreferenceHART DJ, 1993, J RHEUMATOL, V20, P331-
dc.description.citedreferenceFELSON DT, 1992, ANN INTERN MED, V116, P535-
dc.description.tc9-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share